Abstract Almost half of breast Ductal Carcinoma in situ are likely to remain non threatening in situ lesions with no invasion to the surrounding stroma and no metastases. The majority of focal disruptions in myoepithelial (ME) cell layers indicative of invasion onset were found to be overlying epithelial cell clusters with no or substantially reduced estrogen receptor a (ERa) expression. Here we report the down-regulation of tyrosine kinase-2 (TYK2) and up-regulation of strumpellin expression, among other proteins in ERa(-) cells located at disrupted ME layers compared to adjacent ERa(?) cells overlying an intact myoepithelial layer. ERa(?) and ERa(-) cells were microdissected from the same in vivo human breast cancer tissues, proteins were extracted and separated utilizing Differential in-Gel Electrophoresis followed by trypsin digestion, MALDI-TOF analysis, and protein identification. Proteins expressed by ERa(-) cell clusters were found to express higher levels of strumpellin that binds to valosin-containing protein (VCP) to slow-down wound closure and promote growth; and lower levels of TYK2, a jak protein necessary for lineage specific differentiation. TYK2 levels were further analyzed by immunohistochemistry in a cohort composed of 70 patients with broad clinical characteristics. TYK2 levels were minimal in TxN1M0 breast cancers which is the stage where the initial regional lymph node metastasis is observed. Our data highlight the role of TYK2 downregulation in breast cancer cell de-differentitation and initiation of regional metastasis. In addition, the aggressiveness of the ERa(-) cell clusters compared to ERa(?) ones present in the same duct of the same patient was confirmed.
Introduction
Human ductal carcinoma in situ (DCIS) is one of the earliest identifiable breast cancer pathologies. DCIS tumor cells remain confined to the duct and surrounded by a layer of myoepithelial (ME) cells and the basement membrane [1] . Only half of DCIS cases may eventually progress to invasive cancer. Many are likely to remain non-threatening lesions, complicating the determination of the best treatment regimen for DCIS patients. Normal breast ducts are surrounded by ME cell layer and basement membrane that form a physical barrier between the stroma and the luminal epithelium. The ME cells bound to each others by tight intercellular junctions and adhesion molecules, form a continuous layer that encircles the entire duct system. The basement membrane forms a continuous lining surrounding and attaching to ME cells via hemidesmosomes and focal adhesion complexes. Therefore, the epithelium is dependent upon the stroma for its survival needs. Communication between the epithelium and the stroma is regulated by the gate-keeping function of the ME layer and the basement membrane forcing ductal tumor cells to first break their way into the stroma through the ME cell layer, and the basement membrane followed by invasion and metastases [2] .
Immunohistochemical analysis and genetic profiles in adjacent epithelial cells were carried out to analyze their correlation with the structural integrity of the ME cell layer. Focal disruptions were found to be bound by epithelial cell clusters with no or substantially reduced ERa expression, while adjacent cells within the same duct expressed high levels of ERa and were surrounded by an intact ME cell layer [3] . This implies that disruption of this ME layer is a pre-requisite for invasion. Immunohistochemical assessment of showed that cell clusters overlying focally disrupted ME layers showed a substantially higher proliferation rate when compared to adjacent cells within the same duct [4, 5] . The roles played by estrogen receptors, in general, and ERa, in particular, during breast cancer progression and treatment have been previously reviewed [6] . In addition, we recently compared the protein profiles of whole ERa(?) breast cancer tissues to whole ERa(-) ones and identified 22 differentially expressed proteins [7] . Unlike whole breast tissues, which are usually contaminated with ME and stromal cells, microdissected samples yield more homogeneous ERa(?) and ERa(-) cells. These microdissected samples can now give a better assessment of the differential protein profiles present in ERa(?) and ERa(-) breast cancer cells.
Using standard proteomic analysis, we identified differentially expressed proteins in three pairs of microdissected ERa(?) and ERa(-) breast cancer cells using DIGE. Among the identified candidates, TYK2, a protein that belongs to the JAK family of non-receptor tyrosine kinases was found to be consistently down-regulated in ERa(-) compared to adjacent ERa(?) cancer cells. TYK2 was picked for further validation due to its paramount role in the transduction of cytokine-mediated signals, namely type I interferon (IFN) signaling using the JAK-STAT pathway [8, 9] . Validation of our proteomics data utilizing tissue microarrays (TMA) composed of a cohort of 70 patients (140 tissues) with different breast pathologies revealed that TYK2 is mostly down-regulated during metastasis to the regional lymph nodes. This finding supports the hypothesis that primary immunodeficiency through TYK2 down-regulation is required for initial nodal metastasis in breast cancer. The role that TYK2 down-regulation plays in ERa(-) cells neighboring disrupted myoepithelial layers was addressed and the effect of TYK2 downregulation in ERa(?) mammary epithelial cells (MCF-10A) was also analyzed.
Materials and methods
Research involving human subjects was performed in accordance with the principles outlined in the declaration of Helsinki (1964) . Freshly frozen breast tissue samples and corresponding slide-mounted, serial-sectioned paraffinembedded tissues were provided by the tissue bank at Georgetown University Medical Center, Washington, DC 20007. The tissue microarray (TMA) was purchased from Biomax.us (Cat # BR1503). Clinical characteristics are in Table 1 . Specification sheet is in Table S1 (supplemental material).
Immunohistochemical staining (IHC) and tissue microdissection IHC was performed on the TMA and on the Breast DCIS sections as described previously [7] . Rabbit anti-smooth muscle actin (Epitomics Inc., Burlingame, CA) and Mouse anti-ERa (NCL-ER-6F11, Vector Labs, Burlingame, CA) were used at 1:1000 dilution. Rabbit anti-TYK2 (Abcam, Cambridge, MA) was used at a 1:1500 dilution. Unstained adjacent serial sections were used to microdissect clusters overlying myoepithelial disruptions, composed primarily of ERa(-) cells by laser-capture microdissection (LCM). Clusters of ERa(?) cells from the same duct, but bound by an intact ME layer, were similarly obtained. Sections were 5-20 lm thick. One out of three sections was immunostained for ERa to differentiate between ERa(?)/ERa(-) clusters, and epithelial/stromal components and to allow for a precise localization by extrapolation of the ERa(?) and ERa(-) status on the unstained tissues that will be microdissected. This allowed for the isolation of *300 K cells resulting in the extraction of *210 lg of proteins from all three patients, suitable for differential proteome profiling procedures.
Protein extraction and quantitation
Microdissected tissues were homogenized in a tissue lysis buffer composed of 10 mM Tris, 6 M UREA, 4% CHAPS (pH 7.5). The ratio of the volume of tissue lysis buffer added to the weight of the tissue was 1/1 (v/v) and quantitated as described previously [10] .
Protein-dye labeling, DIGE, and image analysis These experiments were optimized and performed as described previously [11] with the following alterations: 15 lg of each of the three pairs of biological replicates of ERa(?) and ERa(-) cell extracts were labeled with 200 pmol of either Cy3 or Cy5. Cy3 and Cy5 were swapped among ERa(?) and ERa(-) samples. An internal standard sample composed of equal amounts of ERa(?) and ERa(-) samples was labeled with Cy2 dye using the same procedure. Labeled proteins were pooled into three different fractions. Each fraction was diluted with rehydration buffer (50 mM Tris-HCl pH 8.8, 6 M Urea, 4% CHAPS (w/v), 1% DTT (w/v), 1% Bio-lyte 3/10 Ampholyte) to a final volume of 450 ll and run on three separate gels (three analytical gels). The remaining protein samples (120 lg) were combined and loaded on the ''pick gel''. The pick gel is the gel that will be used for spot picking and protein identification after matching the spots which exhibited differential intensities on the analytical gels with those on the ''pick gel''.
Sample preparation for MALDI-TOF/TOF analysis and protein identification Protein digestion and peptide recovery procedures leading to the deposition of the peptide-matrix mixture onto the MALDI target plate were performed as described previously [11] . MS analysis was performed using a 4800 MALDI TOF/ TOF mass spectrometer (Applied Biosystems, Foster city, CA). The instrument was calibrated using Applied Biosystems calibration standards. MALDI-TOF spectra were acquired by accumulating 1,000 laser shots in reflector mode for positive ion detection between 800 and 4,000 m/z as described in [11] . MS Mass lists were picked by the GPS Explorer v3.5 software and submitted to the MASCOT v.2.0.00 search engine utilizing the same settings as in [12] .
Western blotting
Western blotting was performed as described previously [13] .
IHC grading and statistical analysis IHC evaluation was performed by a pathologist according to the semi-quantitative IHC scoring system that assesses intensity and distribution of TYK2 immunostaining. TYK2 staining covering less than 10% of tumor cells was given a score of 0; if it covered 10-30% of tumor cells the assigned score was 1; if 30-60% of tumor cells are stained, the score was 2; a score of 3 was given if more than 60% of the tumor cells were TYK2 positive. Intensity was assigned a score of 0 for negative; 1 for weak; 2 for moderate; and 3 for intense. The final score is the product of the distribution score (0, 1, 2, 3) by the intensity score (0, 1, 2, 3) resulting in score values between 0 and 9. TYK2 intensity mean and standard deviation were calculated for each breast condition. For the comparison of three or more means, a one-way analysis of variance (ANOVA) was performed on the means of TYK2 IHC scores in different pathologies. For the comparison of two means, a two-tailed unpaired t-test was performed. P values were generated for both tests. Values of P \ 0.05 corresponding to a confidence interval[95% indicated that differential TYK2 levels between the analyzed breast pathologies are statistically significant.
MCF-10A cell culture, TYK2 knock-down, and protein extraction MCF-10A cells (ATCC: CRL10317) were cultured, passaged, and maintained according to ATCC recommendation.
Clin Exp Metastasis (2012) 29:143-153 145 TYK2 knock-down was performed using 200 pmol of ONTARGETplus SMARTpool TYK2 siRNA (Dharmacon, cat. # L003182) or scrambled siRNA per million cells. TYK2 knock-down and protein extraction were performed as described previously [14] .
Wounding assay
Migration of TYK2 knocked-down MCF-10A ERa(?) breast epithelial cells versus control were assessed by measuring the movement of cells into a scrape, ''wound assay''. The assay was terminated when the wound in MCF10A cells treated with TYK2 siRNA was completely closed, which occurred at 20 h. The assay was performed three times. t-test P values and standard deviations were computed.
Boyden chamber assay
Matrigel invasion assay (chemoinvasion) of TYK2 knocked-down MCF-10A cells was assessed using BD Fluoroblok inserts (8 lm pore size, 24 well format, BD Biosciences) and EGF as chemoattractant. Using sterile forceps, cell wall inserts were added to each well (24 well plate). 30 ll of 1:5 diluted Matrigel was added to the center of each well. Coated inserts were incubated for 30 min to allow the Matrigel to solidify. 2 9 10 5 cells per sample were plated in 200 ll DMEM/F12 onto the upper chamber. Immediately 400 ll/well of complete medium were added in addition to EGF chemo-attractant to the lower chamber. After 24 h, cells that passed through the pores of the membranes and attached themselves to the bottom side were stained with Calcein AM (Invitrogen) and fixed using 10% formalin/0.1% triton. Pictures were taken using a confocal microscope (Zeiss LSM 510-10x). The assay was perfomed three times and t-test P values were generated. Invading cells were counted using the ''Counting cell'' application module of Metamorph software.
Collagen gel assay A pre-set layer of bovine collagen gel (3.0 mg/ml) was prepared in the culture dish. Cells were seeded onto mats of Collagen I. A 1:1 ratio of collagen gel and TYK2 knockeddown MCF-10A or control cells were added on top of the pre-set layer at time t = 0 min and incubated at 37°C. Complete media was added at time t = 30 min. Pictures were taken at t = 0; 5; and 24 h using an inverted microscope (Olympus IX 71-20x) to examine the morphology of the cells.
Results

IHC and microdissection of ERa(?) and ERa(-) cell clusters
Less than 2% of the analyzed breast samples showed the described clusters of cells with ERa(-) cells bound by a focally disrupted ME layer as described in [4] . Breast tissues from three patients matching the above conditions were isolated after immunostaining for ERa. IHC revealed the presence of ERa(-) cells overlying a focally disrupted ME layer and ERa(?) cells overlying an intact ME layer (Fig. 1a-d) . Microdissection of the epithelial ERa(?) and ERa(-) breast cancer tissues yielded homogeneous samples minimizing the presence of contaminating myoepithelial and stromal cells. ERa(?) and ERa(-) cells were microdissected from up to 200 ducts/patient. After cutting thick tissue sections, up to 1,000 cells were obtained from each duct, the majority of which are ERa(?) cells. A total of three pairs of samples were generated. Although not combined initially, the final yield of total proteins extracted Fig. 1 Ducts are immunostained for ERa (brown), SMA (red), and counterstained with hematoxylin (blue): a, b, c IHC tissues from three patients showing ERa(-) cell clusters overlying focally-disrupted ME layer (circled); d higher magnification of c showing the ME layer (arrowhead) and the ME disruption adjacent to ERa(-) cells; e ERa Western blotting on microdissected tissues; f Dye labeling of the three pairs of protein samples which were extracted from the microdissected tissues from these cells amounted to *210 lg. Western blotting against ERa was performed as a quality control to assess the presence of ERa in the samples after loading 1 lg of total proteins from each sample. Immunoblotting for tubulin-a was performed as control. ERa was only detected in ERa(?) and not in ERa(-) microdissected cells (Fig. 1e) .
TYK2 down-regulation in ERa(-) microdisected cells
Fifteen microgram of proteins from each of the six samples were labeled with Cy3 or Cy5 fluorophores. Dyes were swapped across the samples as listed in (Fig. 1f) . Each pair of sample was separated on the same gel. Protein spots were detected for each sample using distinct excitation wavelengths for each dye and detecting the corresponding emission. The remaining protein samples (*120 lg) were combined and loaded on the pick gel. Differential spot intensities on the analytical gels (Fig. 2a) were analyzed and quantitated by the DeCyder2D and Biological Variation Analysis (BVA) tool respectively (GE Healthcare, Buckinghamshire, UK). t-test was applied on two populations: population one consists of n = 3 microdissected ERa(?) and population 2 consists of n = 3 microdissected ERa(-) breast cancer cells. Spots that were differentially detected on the analytical gels across the three pairs of samples with a confidence interval of 95% were picked for excision from the Pick gel, digestion and MS-based identification.
A total of 111 spots were differentially expressed across the three paired samples (t \ 0.05) and 63 of these spots had a match on the pick gel. The pick gel was loaded with 120 lg of the remaining mixture of proteins extracted from both ERa(?) and ERa(-) cells and stained with Sypro Ruby (Fig. 2b) . Excised gel fragments were digested with trypsin and analyzed utilizing a 4800 MALDI-TOF/TOF mass spectrometer (Applied Biosystems, Foster city, CA). MS and MS/MS peak lists were picked by GPS Explorer v3.5 (Applied Biosystems, Foster city, CA) and submitted to MASCOT v.2.0.00 for scanning against a combined Uniprot?SwissProt database composed of more than 255,000 human protein entries. Proteins were identified based on their molecular mass, isoelectric point, and trypsin-generated peptide fingerprints. Out of the 63 spots, 10 were identified (Table 2 ). Differentially expressed proteins that were identified included highly abundant proteins (e.g. tubulins, HSPs, NUMA) in addition to other proteins that are repeatedly identified as being differentially-expressed (e.g. peroxiredoxins, enolases, piruvate kinases). These proteins were not considered in the study. The remaining list of differentially expressed proteins was composed of tyrosine kinase 2 (TYK2) with 16 matching peptide fingerprints ( Fig. 2c ; Supplemental Table S2 ) and Strumpellin (STRUM) with 15 matching peptide fingerprints ( Fig. 2d ; Supplemental Table S3 ). Isoelectric points and molecular weights of identified proteins were confirmed on the analytical and pick gels. Strumpellin levels were 3.05 times higher in ERa(-) when compared to the ERa(?) expression across the three paired samples with a t = 0.041. Non-receptor TYK2 levels were 6.02 times lower in ERa(-) cells when compared with ERa(?) across the three paired samples with a t = 0.0054.
TYK2 expression levels relative to hormone receptors and node status
While using a large cohort of ERa(?) and ERa(-) microdissected tissues to yield a statistically-significant validation of our proteomics data is the mainstay for confirming protein identities, such experiment is limited by the low number of patients with a focal ME disruption adjacent to an ERa(-) cell cluster. We instead opted to analyze TYK2 differentialexpression levels in breast cancer tissues as it relates to hormone receptors and initial invasion since these are the characteristics of the microdissected cells where TYK2 levels were originally found to be downregulated. A TMA containing 140 cores from 70 patients was stained against TYK2. The clinical characteristics of the samples are in Table S1 . IHC staining revealed a significant decrease in TYK2 expression levels in ERa(-) breast cancer tissues compared to ERa(?) ones regardless of other factors (t-test; P \ 0.0001) (Fig. 3a, b) . Further analysis revealed a significant decrease in TYK2 levels in PR(-) compared to PR(?) breast tissues (t-test; P = 0.0006) (Fig. 3c, d ) also regardless of the status of other receptors. The same observation was also noticed in triple(-) tissues versus triple(?) ones (t-test; P = 0.0005) (Fig. 3e, f) . Her2(-) tissues displayed lower TYK2 levels when compared to Her2(?) but the difference was not statistically significant (data not shown). Cells in all the receptor negative breast cancers showed less differentiation than their positive counterparts. A representative set of four tissues of each of the following groups is shown in (Fig. 4a) : normal, N0, N1, and N2. A significant association between TYK2 levels and node status was observed between the populations: Normal and N 0 (t-test P \ 0.0001); N 0 and N 1 (t-test P = 0.0491); N 1 and N 2 (t-test P = 0.0144) (one-way ANOVA; P = 0.0018). TYK2 levels decreased between normal and N0; N0 and N1; and then increased between N1 and N2 (Fig. 4b) . The same trend was observed when TYK2 levels were analyzed relative to breast cancer stage and was found to be statistically significant. TYK2 levels decreased between normal and benign; benign and Stage I; Stage I and Stage IIa; Stage IIa and Stage IIb reaching a minimum expression level for Stage IIIa and then increasing between Stage IIIa and IIIb (one-way ANOVA; P = 0.0001) (Fig. 4c) . A general diagram in Fig. 5 revealed that TYK2 levels were lowest in N1, T2N1/2M0, Stage IIIa, ERa(-) breast cancers and highest in normal, benign, and triple(?) breast cancers (one-way ANOVA; P \ 0.0001). Knockdown of TYK2 induces decreased migration and cell invasion in ERa(?) MCF-10A human breast epithelial cells TYK2 knock-down in MCF-10A cells neither affected the levels of ERa expression (Fig. 6a) nor the cell morphology (Fig. 6b) . Cell morphology pictures were taken on collagen I gels, because it's a setting that mimics the stromal microenvironment of the epithelial cells. Some of the initially seeded cells died and most of the cells showed an aggregated morphology in both TYK2 knock-down MCF-10A and control cells. Changes in migration and invasion due to TYK2 knock-down were analyzed using a scratch/ wound assay and Boyden chamber assay, respectively. The rate of gap closure of the monolayer decreased significantly by 11.93% at 4 h (P = 0.0126) and by 31.08% at 8 h (P = 0.0063) in TYK2 knock-down MCF-10A when compared to control cells (Fig. 6c, d ). In the Boyden chamber Matrigel invasion (chemoinvasion) assay, knockdown of TYK2 caused a 31.76% decrease in chemoinvasion of mammary epithelial cells (P \ 0.05) (Fig. 6e) . Therefore, TYK2 loss results in decreased cell Triple(-) breast cancers. P values were generated following the application of an unpaired t-test migration and chemoinvasion in ERa(?) normal human mammary epithelial cells in vitro.
Discussion
The heterogeneous nature of the breast physiology is hindering the research progress that should lead to breast cancer prevention and treatment. Breast tissues are composed of epithelial, myoepithelial, and stromal cells. Microdissection of the epithelial ERa(?) and ERa(-) breast cancer tissues from human in vivo breast cancer tissues was coupled with DIGE analysis which allows for the separation and the differential protein analysis of scarce samples due to the highly sensitive detection afforded by fluorophores. TYK2 and STRUM, among other proteins, were identified as down and up-regulated respectively in ERa(-) microdissected cell clusters that are adjacent to a focally-disrupted ME layer. Strumpellin per se was recently identified as a VCP-interacting protein and as a ubiquitously-expressed protein located in the cytosolic and endoplasmic reticulum fractions [15] . Overexpression of strumpellin has been associated with significantly reduced wound closure in wound healing assays [15] . Therefore, its upregulation in the ERa(-) bound by a disrupted myoepithelial layer may play a dual role in promoting tumor growth and invasion. A major discrepancy in the result is the absence of ERa from the list of differentially-expressed proteins. ERa was supposed to be one of the most downregulated proteins in ERa(-) samples since this sample is composed solely of ERa(-) extracts as shown in the Western blotting results (Fig. 1e) . The isoelectric point (pI) of ERa is 8.2 making it prone to precipitation since it is close to the pH of the separation buffer (pH 7.5). Fig. 4 a Representative set of breast tissues immunostained against TYK2 and association between TYK2 expression levels and b node status regardless of tumor size, P values were generated following the application of a ttest; and c breast cancer stage P values were generated following one-way ANOVA Fig. 5 Summary of TYK2 expression levels in normal, benign, ERa, PR, Her2, triplereceptor status, TNM groups, breast cancer stages, and node status regardless of tumor size. P value (\0.001) was generated for all sub-groups following one-way ANOVA. Unpaired ttests between specific subgroups were generated and described in the previous figures Furthermore, nuclear proteins have been described as moderately soluble and all successful attempts at increasing their solubility required high concentrations of thiourea and urea in the lysis buffer in addition to the use of high loads of proteins [16] , which cannot be afforded in the current study. Furthermore, 2DE technology allows for the visualization of only 2-10% of the sample proteome. Granted some proteins have a higher chance of being detected on 2DE due to their high abundance and solubility in aqueous solvents, most proteins have a 2-10% detection chance. TYK2 was picked for further analysis in breast cancers due to its important role in the transduction of cytokinemediated signals, namely type I interferon (IFN) signaling using the JAK-STAT pathway [8, 9] . TYK2 is one of four mammalian jaks that belongs to the family of Janus Kinases (Jak) associated with cytokine receptors [17] . TYK2 was initially thought to be essential for type I IFN signaling in human fibroblast cells [18] . Lately, a study by Minegishi et al. [19] showed that TYK2 deficiency in patients causes severe defects in IL-6 and IL-10 signaling resulting in hyper IgE syndrome (HIES) which is a primary immunodeficiency characterized by skin abscesses, pneumonia, and high levels of IgE [20, 21] . Although high levels of IgE are most commonly associated with allergic and parasitic diseases, a study showed that resistant breast tumor recurrence rate was significantly higher in patients with elevated IgE levels [22] . Therefore, TYK2 downregulation in ERa(-) cells resulting in HIES is a signal of bad prognosis, and therapy-resistant breast cancer. This is also in agreement with previous studies that showed that ERa(-) cell clusters in DCIS with microinvasion may represent a clone from a genetically-altered cancer stem cell, explaining why many of the differentiation markers are not expressed or are expressed at a much lower level than those of adjacent ERa(?) cells. These results suggest that ERa(-) cell clusters may arise from dedifferentiated proliferating ERa(?) breast cancer cells rendering them pathologically more aggressive and resistant to treatment [23] . Furthermore, TYK2 down-regulation in vitro results in the deactivation of downstream target STAT3 and therefore a reduced response to growth arrest conditions [24] .
The above-described pathology is only present in 2% of breast cancer samples making the recruitment of a large cohort to validate the proteomic finding on breast cancers practically impossible. To compensate, we used tissue microaarays (TMA) containing 140 tissues from 70 patients stained against TYK2. These tissues are characterized by different breast cancer stages labeled according to TNM (Tumor-Nodes-Metastasis) system. In concordance with the proteomics data, TYK2 was found to be significantly down-regulated in ERa(-) breast cancers regardless of the node status, and to be minimally expressed in TxN1M0 cancers regardless of the tumor size.
At cancer stages that preceded TxN1M0 (TxN0M0) and followed it (TxN2M0), breast tissues expressed significantly higher TYK2 levels. TxN1M0 is the stage of the initial metastasis of cancer cells to regional lymph nodes. The JAK-STAT pathway is known to be involved in the process of differentiation and proliferation [25] . Moreover, TYK2 was particularly found to be necessary for lineagespecific differentiation [26] , and its levels were found to be elevated in invasive and metastatic cancers [27, 28] . Therefore, we believe that the drop in TYK2 levels is required for the de-differentiated ERa(-) beast cancer cells to initiate metastasis to regional lymph nodes. We performed morphology, migration, and cell invasion assays in MCF-10A ERa(?) breast cells following TYK2 knockdown. No changes in the morphology or ERa expression levels were observed as a consequence of TYK2 downregulation. Contrary to the role it plays in the ERa(-) dedifferentiated cells, TYK2 knock-down in MCF-10A ERa(?) mammary epithelial cells caused a statistically significant decrease in migration and chemo-invasion pointing that the role of TYK2 is not independent and that other members of the jak/STAT pathway are involved in the initiation of invasion.
The JAK-STAT pathway was considered a favorable prognostic marker for lymph node negative breast cancers as it is attributed to a more differentiated phenotype within the primary lesion [29] . Furthermore, the JAK-STAT pathway was found to promote homotypic adhesion, thus suppressing invasiveness [30] . Our data are in full agreement with in vitro studies that compared TYK2 levels in different breast cancer cell lines and found them to be higher in ERa(?) cell lines (T47D, MCF7, ZR-75-1) when compared to ERa(-) lines (MDA-MB-231, BT549, HS578T, MDA-MB-435S), and immortalized normal lines (MCF10A, MCF12A, and Hs578Bst) [31] . Interestingly, among all breast cancer cell lines analyzed in the latter study, TYK2 levels were the lowest in BT549, a cell line derived from an invasive ductal tumor that had metastasized to 3 of 7 regional lymph nodes [31] .
In summary, proteins expressed by ERa(-) cell clusters overlying a focally disrupted myoepithelial layer were compared to those expressed by ERa(?) cell clusters overlying an intact myoepithelial layer. ERa(-) cell clusters showed higher levels of strumpellin that binds to VCP to slow-down wound closure and promote growth; and lower levels of TYK2 a jak protein whose levels are the lowest during the initiation of regional lymph node metastasis. Collectively, these results can explain, in part, the aggressiveness of the ERa(-) cells compared to ERa(?) counterparts present in the same duct of the same patient, and the importance of TYK2 downregulation at the initiation of nodal metastasis in de-differentiated ERa(-) breast cancer cells .
